Improving the quality of care for women with cardiovascular disease. Report of a DCRI Think Tank, March 8 to 9, 2007

American Heart Journal

Volumn 156, Issue 5, 2008, Pages

  Berger, Jeffrey S ^a   Bairey Merz, C Noel ^b   Redberg, Rita F ^c   Douglas, Pamela S ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Cardiology Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; DIAGNOSTIC PROCEDURE; DRUG USE; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REIMBURSEMENT; RISK ASSESSMENT; SUDDEN DEATH; SYSTEMATIC REVIEW; TIME SERIES ANALYSIS;

EID: 54849439911     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.06.039     Document Type: Article

References (82)

1. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Women. World Heart Federation Web site. Available at. http://www.worldheart.org/awareness-women.php Last accessed October 27, 2007
3. Shaw L.J., Bairey Merz C.N., Pepine C.J., et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 47 (2006) S4-S20
4. Blomkalns A.L., Chen A.Y., Hochman J.S., et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 45 (2005) 832-837
5. Chou A.F., Wong L., Weisman C.S., et al. Gender disparities in cardiovascular disease care among commercial and Medicare managed care plans. Womens Health Issues 17 (2007) 139-149
6. Jacobs A.K., Johnston J.M., Haviland A., et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol 39 (2002) 1608-1614
7. Malenka D.J., Wennberg D.E., Quinton H.A., et al. Gender-related changes in the practice and outcomes of percutaneous coronary interventions in Northern New England from 1994 to 1999. J Am Coll Cardiol 40 (2002) 2092-2101
8. Epstein A.M., Weissman J.S., Schneider E.C., et al. Race and gender disparities in rates of cardiac revascularization: do they reflect appropriate use of procedures or problems in quality of care?. Med Care 41 (2003) 1240-1255
9. Roger V.L., Jacobsen S.J., Weston S.A., et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med 136 (2002) 341-348
10. Ford E.S., and Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol 50 (2007) 2128-2132
11. Giles W.H., Anda R.F., Casper M.L., et al. Race and sex differences in rates of invasive cardiac procedures in US hospitals. Data from the National Hospital Discharge Survey. Arch Intern Med 155 (1995) 318-324
12. Hernandez A.F., Fonarow G.C., Liang L., et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 298 (2007) 1525-1532
13. Mensah G.A., Mokdad A.H., Ford E.S., et al. State of disparities in cardiovascular health in the United States. Circulation 111 (2005) 1233-1241
14. Lee P.Y., Alexander K.P., Hammill B.G., et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 286 (2001) 708-713
15. Johnson S.M., Karvonen C.A., Phelps C.L., et al. Assessment of analysis by gender in the Cochrane reviews as related to treatment of cardiovascular disease. J Women's Health 12 (2003) 449-457
16. Harris D.J., and Douglas P.S. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 343 (2000) 475-480
17. Blauwet L.A., Hayes S.N., McManus D., et al. Low rate of sex-specific result reporting in cardiovascular trials. Mayo Clin Proc 82 (2007) 166-170
18. Heiat A., Gross C.P., and Krumholz H.M. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162 (2002) 1682-1688
19. Wizemann T.M., and Pardue M.L. Exploring the biological contributions to human health: does sex matter? (2001), National Academies Press, Washington, DC
20. National Institutes of Health. Problems in implementing policy on women in study populations (1990), US General Accounting Office, Washington, DC Publication GAO/T-HRD-90-38
21. National Institutes of Health guidelines on the inclusion of women and minorities as subjects in clinical research, 59 Federal Register. 11146 (1994).
22. Gray J., and Stewart M. Looking at research through a different lens: The Canadian Institute of Gender and Health. Clin Pharmacol Ther 83 (2008) 188-191
23. Califf R.M., Peterson E.D., Gibbons R.J., et al. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol 40 (2002) 1895-1901
24. Bairey Merz C.N., Shaw L.J., Reis S.E., et al. Insights from the NHLBI-Sponsored WISE Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 47 (2006) S21-S29
25. Pilote L., Dasgupta K., Guru V., et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 176 (2007) S1-S44
26. US General Accounting Office. Drug safety: most drugs withdrawn in recent years had greater health risks for women. Available at. http://www.gao.gov/new.items/d01286r.pdf Last accessed January 7, 2008
27. Dhruva S., and Redberg R. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions. Arch Intern Med 168 (2008) 136-140
28. McEntegart D. The pursuit of balance using stratified and dynamic randomization techniques: an overview. Drug Inf J 37 (2003) 293-308
29. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
30. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
31. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
32. Lovato L.C., Hill K., Hertert S., et al. Recruitment for controlled clinical trials: literature summary and annotated bibliography. Control Clin Trials 18 (1997) 328-352
33. Ding E.L., Powe N.R., Manson J.E., et al. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. Arch Intern Med 167 (2007) 905-912
34. Mapstone J., Elbourne D., and Roberts I. Strategies to improve recruitment to research studies. Cochrane Database Syst Rev (2007) MR000013
35. Fouad M.N., Corbie-Smith G., Curb D., et al. Special populations recruitment for the Women's Health Initiative: successes and limitations. Control Clin Trials 25 (2004) 335-352
36. Berger J.S., Roncaglioni M.C., Avanzini F., et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006) 306-313
37. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359 (2002) 189-198
38. Walsh J.M., and Pignone M. Drug treatment of hyperlipidemia in women. JAMA 291 (2004) 2243-2252
39. Makkar R.R., Fromm B.S., Steinman R.T., et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270 (1993) 2590-2597
40. Alexander K.P., Chen A.Y., Newby L.K., et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. Circulation 114 (2006) 1380-1387
41. Mark D., Hodgson P., and Califf R. What we publish in the American Heart Journal and why. Am Heart J 154 (2007) 1-2
42. Oliva A., Pinnow E., Levin R., et al. Improving women's health through modernization of our bioinformatics infrastructure. Clin Pharmacol Ther 83 (2008) 192-195
43. Senator Debbie Ann Stabenow (D-MI). Heart Disease Education, Analysis and Research Act (S.573, 2006). Available at. http://www.govtrack.us/congress/bill.xpd?bill=s109-2278 Last accessed September 1, 2008
44. Representative Lois Capps (D-CA). Heart Disease Education, Analysis and Research Act (H.R. 1014, 2007). Available at. http://www.govtrack.us/congress/bill.xpd?bill=h110-1014 Last accessed September 1, 2008
45. Mosca L., Linfante A.H., Benjamin E.J., et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 111 (2005) 499-510
46. Mosca L., Ferris A., Fabunmi R., et al. Tracking women's awareness of heart disease: an American Heart Association national study. Circulation 109 (2004) 573-579
47. Mosca L., Mochari H., Christian A., et al. National study of women's awareness, preventive action, and barriers to cardiovascular health. Circulation 113 (2006) 525-534
48. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
49. Aspirin for TIA's. FDA Drug Bull 10 (1980) 2-5
50. Hennekens C.H. Aspirin in the treatment and prevention of cardiovascular disease. Annu Rev Public Health 18 (1997) 37-49
51. Aspirin for heart patients. FDA Drug Bull 15 (1985) 34-36
52. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the ACC/AHA Task Force on Practice Guidelines. J Am Coll Cardiol 50 (2007) e157
53. Becker D.M., Segal J., Vaidya D., et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295 (2006) 1420-1427
54. Cavallari L.H., Helgason C.M., Brace L.D., et al. Sex difference in the antiplatelet effect of aspirin in patients with stroke. Ann Pharmacother 40 (2006) 812-817
55. Chiang N., Hurwitz S., Ridker P.M., et al. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol 26 (2006) e14-e17
56. Hochman J.S., Tamis J.E., Thompson T.D., et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. GUSTO in Acute Coronary Syndromes IIb Investigators. N Engl J Med 341 (1999) 226-232
57. Merz N.B., Johnson B.D., Kelsey P.S.F., et al. Diagnostic, prognostic, and cost assessment of coronary artery disease in women. Am J Manag Care 7 (2001) 959-965
58. Mieres J.H., Shaw L.J., Arai A., et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement. Circulation 111 (2005) 682-696
59. Pepine C.J., Kerensky R.A., Lambert C.R., et al. Some thoughts on the vasculopathy of women with ischemic heart disease. J Am Coll Cardiol 47 (2006) S30-S35
60. Mieres J.H., Shaw L.J., Hendel R.C., et al. American Society of Nuclear Cardiology consensus statement: Task Force on Women and Coronary Artery Disease-the role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women. J Nucl Cardiol 10 (2003) 95-101
61. Anderson K.M., Wilson P.W., Odell P.M., et al. An updated coronary risk profile. A statement for health professionals. Circulation 83 (1991) 356-362
62. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105 (2002) 310-315
63. Ferrario M., Chiodini P., Chambless L.E., et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol 34 (2005) 413-421
64. Ridker P.M., Buring J.E., Rifai N., et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297 (2007) 611-619
65. Glaser R., Herrmann H.C., Murphy S.A., et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 288 (2002) 3124-3129
66. Newby L.K., Ohman E.M., Christenson R.H., et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation 103 (2001) 2891-2896
67. Morrow D.A., Cannon C.P., Rifai N., et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 286 (2001) 2405-2412
68. O'Donoghue M., Sabatine M., Boden W., et al. The benefit of an early invasive strategy in women with non-ST-elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. Circulation 116 (2007) II-383
69. Lagerqvist B., Safstrom K., Stahle E., et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol 38 (2001) 41-48
70. Fox K.A., Poole-Wilson P.A., Henderson R.A., et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 360 (2002) 743-751
71. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
72. Freedman J.E., Becker R.C., Adams J.E., et al. Medication errors in acute cardiac care: An AHA scientific statement. Circulation 106 (2002) 2623-2629
73. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
74. de Teresa E., Alzueta J., and Jimenez-Navarro M. Profiling risk from arrhythmic or hemodynamic death. Am J Cardiol 86 (2000) 126K-132K
75. Kannel W.B., Wilson P.W., D'Agostino R.B., et al. Sudden coronary death in women. Am Heart J 136 (1998) 205-212
76. Ghali J.K., Pina I.L., Gottlieb S.S., et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 105 (2002) 1585-1591
77. Ezekowitz J.A., Rowe B.H., Dryden D.M., et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 147 (2007) 251-262
78. Yarnoz M.J., and Curtis A.B. Sex-based differences in cardiac resynchronization therapy and implantable cardioverter defibrillator therapies: effectiveness and use. Cardiol Rev 14 (2006) 292-298
79. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
80. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
81. Curtis L.H., Al-Khatib S.M., Shea A.M., et al. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 298 (2007) 1517-1524
82. Redberg R.F. Disparities in use of implantable cardioverter-defibrillators: moving beyond process measures to outcomes data. JAMA 298 (2007) 1564-1566